DANBURY, Conn.--(BUSINESS WIRE)--Biodel, Inc. (Nasdaq:BIOD) today reported new information regarding the mechanism of action of VIAject® (injectable prandial insulin) and an update on previously reported findings regarding the effects of VIAject® on microvascular function in patients with type 2 diabetes. VIAject® is an investigational ultra-rapid-acting injectable human insulin which Biodel is developing as a treatment for diabetes.
